KOD
Closed
Kodiak Sciences Inc
3.76
+0.03 (+0.80%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.73
Day's Range: 3.600374 - 3.84
Send
sign up or login to leave a comment!
When Written:
4.76
Kodiak Sciences Inc. is a biopharmaceutical company that focuses on the development of novel therapies for the treatment of retinal diseases. The company's lead product candidate, KSI-301, is a potential treatment for wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). KSI-301 is a novel anti-VEGF antibody biopolymer conjugate designed to provide extended durability in the eye, potentially reducing the need for frequent injections.
Kodiak Sciences was founded in 2009 and is headquartered in Palo Alto, California. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol KOD. The company's management team includes experienced leaders from the biopharmaceutical industry, including CEO Victor Perlroth, MD, and Chief Medical Officer Jason Ehrlich, MD.
Kodiak Sciences has partnerships with major pharmaceutical companies, including Bayer AG and Biogen Inc., to develop and commercialize KSI-301 globally. The company has also received significant funding from venture capital firms, including Arch Venture Partners and Venrock.
In addition to KSI-301, Kodiak Sciences is also developing other product candidates, including KSI-501, a potential treatment for dry AMD, and KSI-201, a potential treatment for non-proliferative diabetic retinopathy.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Kodiak Sciences was founded in 2009 and is headquartered in Palo Alto, California. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol KOD. The company's management team includes experienced leaders from the biopharmaceutical industry, including CEO Victor Perlroth, MD, and Chief Medical Officer Jason Ehrlich, MD.
Kodiak Sciences has partnerships with major pharmaceutical companies, including Bayer AG and Biogen Inc., to develop and commercialize KSI-301 globally. The company has also received significant funding from venture capital firms, including Arch Venture Partners and Venrock.
In addition to KSI-301, Kodiak Sciences is also developing other product candidates, including KSI-501, a potential treatment for dry AMD, and KSI-201, a potential treatment for non-proliferative diabetic retinopathy.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!